Product Pipeline

Our pipeline is focused on targeting significant unmet needs, with a primary focus on developing treatments for movement disorders in the field of neurolology.

In November 2014, Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency (EMA). IPX066 is currently marketed in the U.S. as RYTARY®, an extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease.

In January 2014, Impax and DURECT signed an agreement granting Impax the exclusive worldwide rights to develop and commercialize IPX239, an investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).